10x Genomics ( TXG ) Reports Q3 Loss, Beats Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +18.52% and +4.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
https://www.zacks.com/stock/news/2787234/10x-genomics-txg-reports-q3-loss-beats-revenue-estimates